Danish biotechnology company Biograil announced completion of a EUR 20 million financing round on 4 November 2026. The total includes an EUR 8.5 million first close disclosed in 2025, so the incremental amount added at completion was not stated. Verve Ventures, Megatrend Invest and HTGF Opportunity Fund were named among the investors, with no current lead identified. Biograil is developing an oral capsule that protects biological medicines and releases them through a mechanical delivery system in the intestine. The capital will advance clinical and manufacturing work intended to offer patients an alternative to repeated injections.
Biograil completes EUR 20m financing
Capital supports oral delivery of injectable medicines

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


